Loading patent…
AssigneeIsis Innovation Limited
InventorsAlison Banham, Andrew Campbell, Duncan Gascoyne, Linden Lyne
Estimating the term…
The present invention is directed to a method for detecting abnormal lymphocytes said method comprising detecting an amount or expression of the FOXP2 gene in lymphocytes in a sample, wherein an increased amount or expression of the FOXP2 gene in said lymphocytes indicates the presence of abnormal lymphocytes. Additionally, the invention concerns a method for detecting or assessing a condition associated with the presence of abnormal lymphocytes. The methods of the invention may also be useful for diagnosing myeloma or MGUS or for determining the prognosis for patients with lymphoma, myeloma or MGUS. The severity of bone disease or bone colonisation of tumours may also be able to be predicted. Further, treatment of conditions associated with the presence of abnormal lymphocytes using an agent which inhibits FOXP2 expression and/or FOXP2 activity is provided. An antibody which binds to the N-terminus of FOXP2 has also been developed.
A method for detecting abnormal lymphocytes said method comprising
(canceled)
(canceled)
(canceled)
The method of claim 20 wherein said condition is a plasma cell disorder or is lymphoma.
The method of claim 20 wherein said agent is an antisense sequence, siRNA, a FOXP2 binding protein, small molecule inhibitor, FOXP2 consensus DNA target sequence or an antibody.
The method of claim 20 further comprising administering a therapeutic agent effective against or used in the treatment of a condition associated with abnormal lymphocytes, as a combined preparation for simultaneous, separate or sequential use in treating a condition associated with abnormal lymphocytes.
A method of treating a condition associated with the presence of abnormal lymphocytes in a subject suffering therefrom and/or for reducing the severity of bone disease associated with said condition, comprising administering to said subject an agent which inhibits FOXP2 expression and/or FOXP2 activity.
(canceled)
An antibody that specifically binds the N-terminus of FOXP2.
A hybridoma being that of ECACC deposit Accession No. 08101410.
(canceled)
Dependencies are inferred from the claim text.